

# Carbapenem-resistant *Enterobacteriaceae* (CRE) - The Nightmare Bacteria

Patients infected with Carbapenem-resistant *Enterobacteriaceae* (CRE) have a 40% higher mortality rate since CRE strains can be resistant to all available antibiotics.<sup>1</sup>

Revogene® Carba C provides healthcare systems an opportunity to minimize the burden of CRE through improved care and efficiency.

- Help guide appropriate treatment for patients with known or suspected carbapenem non-susceptible infections by detecting and differentiating the 5 known gene sequences associated with carbapenem resistance<sup>2</sup>
- Fast, actionable results enable clinicians to implement the appropriate infection control protocols<sup>3</sup>
- $\bullet$  Revogene<sup>®</sup> is a flexible, reliable molecular platform that enables healthcare facilities to meet regulatory standards for antibiotic testing<sup>4</sup>

#### Is your healthcare system prepared?

- · Can you detect the carbapenem resistance mechanism of action in patients with CRE?
- · How do you manage infection control in patients with CRE?
- How do you manage antibiotic therapy in patients with CRE?



# revogene

Carba C

#### Stop the Spread

- Alert physicians to the presence of carbapenem non-susceptible gram-negative bacteria by detecting and differentiating the 5 known gene sequences (KPC, NDM, VIM, OXA-48-like, IMP) associated with carbapenem resistance
- The flexibility of the Revogene® Carba C test provides health systems the opportunity to detect emerging CRE genes when they arise

#### Improve Efficiency

- Improve overall lab efficiency with Revogene's simplified sample prep and 2 minutes hands-ontime
- Respond quickly to the threat of carbapenemase-producing organisms by providing results in 70 minutes

#### **Total Trusted Solution**

- Revogene<sup>®</sup> is a flexible molecular platform that can help standardize testing throughout a health system improving clinical efficiencies
- Near patient testing allows clinicians to make treatment and infection control decisions quickly to provide optimal patient care

## Revogene® Carba C Procedure Steps

Sample to Result in 3 Steps Less than 2 minutes hands on time









2 Load Sample into the PIE





## **Product Specifications**

The Revogene® Carba C assay is a simple and direct, qualitative in vitro diagnostic test designed for the detection and differentiation of the blaKPC, blaNDM, blaVIM, blaOXA-48-like, and blaIMP gene sequences associated with carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa, when grown on blood agar or MacConkey agar.

#### **Turnaround Time**

70 minutes for positive and negative samples

#### Sample Type

Carbapenem-non-susceptible pure colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa grown on blood agar or MacConkey agar

#### Sample Storage

2 - 25 C

#### Kit Storage

24 individual pouches

Store at 2 - 25 C until expiration date indicated on kit label and on each pouch

#### Performance\*

Target	Sensitivity	Specificity
NDM	98.9%	99.4%
КРС	99.6%	99.2%
OXA-48-like	100%	99.4%
IMP	100%	95.9%
VIM	100%	99.8%

### **Catalog Number**

**CPT Codes** 

Revogene® Carba C — 133499

87150 x 5

\* This data is a representation of the blood agar and MacConkey agar combined.

#### References

- $1.\ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393012/pdf/12879\_2017\_Article\_2383.pdf$
- 2. Revogene<sup>®</sup> Carba C Package Insert, Ref. #133499
- 3. CDC. Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE); November 2015 Update — CRE Toolkit. CDC National Center for Emerging and Zoonotic Infectious Disease, Atlanta, GA
- Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing;
  29th ed. CLSI Document M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA; 2019

# Ready to get a handle on Carba C testing? Let's talk.

Contact a specialist at 1-888-763-6769.

meridianbioscience.com/contact-us

